Image Source: Unsplash
An Introduction
This article highlights the 10 clinical-stage AI-powered (designated with *) and psychedelic compound-based (designated with **) small cap ($400M to $2.0B) drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and so far in April (MTD), and their areas of focus.
- focuses on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine. Go here for much more extensive information on DMT.
- focuses on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- specializes in offering solutions for both small molecule discovery and biologics discovery focusing on structure prediction and protein engineering, including antibody modeling.
- reported the first AI-designed drug candidate to enter clinical trials and is collaborating with Bristol-Myers Squibb on a handful of drug candidates and has partnered with Sanofi, GSK and PathAI on drug discovery projects.
- focuses on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- develops antibody therapeutics and then outsources their initial findings to their partners for further drug discovery.
- has one of the world’s most extensive biological and chemical datasets and has several compounds in phase 1 and 2 studies, including a small molecule therapeutic for cavernous cerebral malformation and another for neurofibromatosis type 2.
- specializes in developing an artificial intelligence-driven allosteric drug-discovery platform intended to detects and characterizes interactions that occur on a protein of interest and combines computational methods with experimental approaches across the fields of structural biology, biophysics, and chemistry. Its initial focus on precision oncology and genetic diseases.
- focuses on antibody design, creating new from scratch antibodies (“de novo antibodies”), and testing them in laboratories in a 6-week process.
- focuses on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
Summary
On average, the above 10 stocks were DOWN 9.2% last week and are now DOWN 12.0% MTD.More By This Author:All 7 AI Category Portfolios Continued To Decline This Week
Bitcoin Halving Is Happening Saturday; What Could It Mean For Its Future Price?
Update: Israeli Stocks On U.S. Exchanges Have Outpaced Nasdaq And S&P 500 Since October 7/23
